Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified

NCT02526004 | Completed DMC

• 1 other identifier: UCC-CFMATTERS
• Study Type: interventional
• Target: 223
• Locations: 1 country
• Sites: 1

Brief Summary

Antimicrobial resistance is a significant challenge facing global healthcare. The unnecessary use of antibiotics is a key driver in the development of antibiotic resistance. Cystic Fibrosis (CF) represents a unique disease model to study bacterial resistance and to explore therapeutic strategies for same, as chronic lung infection overlaps with acute lung exacerbation's caused by a multitude of organisms. With time, chronic polymicrobial infection develops, with the most dominant infecting organism being Pseudomonas aeruginosa. In acute CF infections, empiric intravenous antibiotics are usually given for two weeks. Recurrent infections and treatments result in increasing antimicrobial resistance, and alterations in pathogen host interactions in the lung and gut flora. Next-generation DNA sequencing technology now offers DNA-based personalised diagnostics and treatment strategies. Enhancing our knowledge of the microbiome allows the use of stratified targeted antibacterial therapy that can be compared with standard empirical antibacterial therapy currently used. Cystic Fibrosis Microbiome-determined Antimicrobial Therapy Trial in Exacerbations: Results Stratified (CFMATTERS) will provide a randomized multi-centre controlled trial of microbiome-derived antimicrobial treatments versus current empirical therapy.

Conditions

Cystic Fibrosis

Keywords

Cystic Fibrosis; Microbiome; Stratified Antibacterial therapy; Resistance; Pathogen Host Interaction

Outcome Measures

Primary Outcomes (1)

• The percentage change in recovery (post-exacerbation) FEV1 relative to the previous pre-exacerbation FEV1.

  Time from enrollment to 14 days post initiation of IV antibiotics for elligible exacerbation.

Secondary Outcomes (6)

• The time to next pulmonary exacerbation

  Time from pulmonary exacerbation day 0, to next pulmonary exacerbation up to study close month 21

• The improvement in symptom burden by day 7 as determined by Cystic Fibrosis Respiratory Symptom Diary (CFRSD)

  Time from pulmonary exacerbation day 0 to day 7 of pulmonary exacerbation

• The improvement in health related quality of life at day 28 post treatment and at 3 months as determined by the Cystic Fibrosis Questionnaire Revised (CFQR)

  Time from pulmonary exacerbation day 0 to day 28 and month 3 post study treatment

• Total number of i.v. antibiotic days (home or in hospital) from time of randomisation in the trial

  Time from enrollment in the study up to study close month 21

• Change in FEV1

  Time from enrollment in the study up to study close month 21

Study Arms (2)

Standard Empiric Treatment

ACTIVE COMPARATOR

Ceftazidime or Aztreonam (in case of Ceftazidime allergy) and Tobramycin

Drug: Ceftazidime; Drug: Tobramycin

Microbiome Guided Treatment

EXPERIMENTAL

Ceftazidime or Aztreonam (in case of Ceftazidime allergy) and Tobramycin and 3rd Antibiotic based on the Microbiome analysis

Drug: Ceftazidime; Drug: Tobramycin

Interventions

Ceftazidime DRUG

Microbiome Guided Treatment; Standard Empiric Treatment

Tobramycin DRUG

Microbiome Guided Treatment; Standard Empiric Treatment

Eligibility Criteria

• Age: 16 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Written and informed consent, and assent where required.
• Age 16 years or older at enrolment
• Diagnosis of CF by standard sweat test and/or genetic analysis
• Persistent pulmonary Pseudomonas aeruginosa colonization confirmed on at least 2 occasions in the preceding 12 months
• Screening FEV1 predicted of \>25%
• Able to perform spirometry reproducibly prior to enrolment
• Able to expectorate and provide a sputum sample at least once daily
• ≥1 non-elective course of intravenous antibiotics in the preceding year
• Able to understand and comply with protocol requirements, restrictions and instructions and likely to complete the study as planned, as judged by the investigator

You may not qualify if:

• Life expectancy less than 6 months
• They are a solid organ transplant recipient
• Have a requirement for immunosuppression ≥10mg corticosteroids per day
• Previous positive culture of non-tuberculosis mycobacteria species M.avium, M.abscessus or M.intracellulare within the last 12 months or undergoing active therapy
• Positive culture of any Burkholderia cepacia species within the last 12 months or undergoing active therapy
• Allergic bronchopulmonary aspergillosis on treatment
• Known allergies to more than 3 different classes of antibiotics, and intolerance or allergy to tobramycin.
• Liver portal hypertension, determined by identification of oesophageal varices
• Advanced kidney disease requiring a dose reduction of ceftazidime or contraindicating aminoglycosides
• History of any illness that in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject
• If patient undergoes a pulmonary exacerbation before the Microbiome analysis is reviewed by the Consensus Treatment Panel and i.v. antibiotics are administered. In this case, a repeat sputum will be sent for analysis 4 weeks after end of antibiotic treatment.
• Pregnant or breast-feeding at time of eligible pulmonary exacerbation

Sponsors & Collaborators

• University College Cork: lead
• Queen's University, Belfast: collaborator
• University of Paris 5 - Rene Descartes: collaborator
• University of Dundee: collaborator
• University of Washington: collaborator
• University Hospital Heidelberg: collaborator
• Teagasc: collaborator
• Clininfo S.A.: collaborator
• GABO:mi: collaborator
• Papworth Hospital NHS Foundation Trust: collaborator
• KU Leuven: collaborator
• Assistance Publique - Hôpitaux de Paris: collaborator
• European Union: collaborator

Study Sites (1)

University College Cork

Cork, Cork, Ireland

Location

MeSH Terms

Conditions

Cystic Fibrosis

Interventions

Ceftazidime; Tobramycin

Condition Hierarchy (Ancestors)

Pancreatic Diseases; Digestive System Diseases; Lung Diseases; Respiratory Tract Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Infant, Newborn, Diseases

Intervention Hierarchy (Ancestors)

Cephaloridine; Cephalosporins; beta-Lactams; Lactams; Amides; Organic Chemicals; Thiazines; Sulfur Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Nebramycin; Kanamycin; Aminoglycosides; Glycosides; Carbohydrates

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Barry Plant, CFMATTERS Coordinator

Study Record Dates

• First Submitted: August 10, 2015
• First Posted: August 18, 2015
• Study Start: October 1, 2013
• Primary Completion: June 30, 2017
• Study Completion: June 30, 2018
• Last Updated: April 10, 2025

Record last verified: 2025-04

Locations

IE (1)